Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 1997 Mar 15;322(Pt 3):893–898. doi: 10.1042/bj3220893

Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content.

M Racchi 1, R Baetta 1, N Salvietti 1, P Ianna 1, G Franceschini 1, R Paoletti 1, R Fumagalli 1, S Govoni 1, M Trabucchi 1, M Soma 1
PMCID: PMC1218272  PMID: 9148766

Abstract

Plasma-membrane composition plays a crucial role in most of the cellular functions that depend on membrane processes. In virtually all cell types the proteolytic processing of Alzheimer amyloid precursor protein (APP) to generate soluble APP (sAPP) is believed to occur at the plasma membrane or in its immediate proximity. Alteration of this metabolic pathway has been linked to the pathogenesis of Alzheimer's disease. We analysed the effect of membrane cholesterol enrichment on APP metabolism. Incubation of COS cells with increasing concentrations of non-esterified cholesterol carried by rabbit beta-very low-density lipoprotein caused a dose-dependent inhibition of sAPP release: 70% inhibition with 10 microg/ml non-esterified cholesterol. A less pronounced inhibitory effect was observed on treatment with human low-density lipoprotein. Inhibition of sAPP release was independent of receptor-mediated lipoprotein metabolism since simultaneous treatment with chloroquine did not modify the effect of lipoprotein treatment. In addition, treatment with cholesterol dissolved in either ethanol or methyl-beta-cyclodextrin elicited the same effect. Excess non-esterified cholesterol did not cause cell toxicity. Cell cholesterol mass inversely correlated with sAPP release. Progesterone, which inhibits shuttling of non-esterified cholesterol between the plasma membrane and intracellular pools, had no effect on the inhibition of sAPP release from cholesterol-loaded cells, providing indirect evidence that cholesterol may act at the plasma membrane.

Full Text

The Full Text of this article is available as a PDF (232.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. P., Esch F. S., Keim P. S., Sambamurti K., Lieberburg I., Robakis N. K. Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells. Neurosci Lett. 1991 Jul 8;128(1):126–128. doi: 10.1016/0304-3940(91)90775-o. [DOI] [PubMed] [Google Scholar]
  2. Arbogast L. Y., Rothblat G. H., Leslie M. H., Cooper R. A. Cellular cholesterol ester accumulation induced by free cholesterol-rich lipid dispersions. Proc Natl Acad Sci U S A. 1976 Oct;73(10):3680–3684. doi: 10.1073/pnas.73.10.3680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Arribas J., Massagué J. Transforming growth factor-alpha and beta-amyloid precursor protein share a secretory mechanism. J Cell Biol. 1995 Feb;128(3):433–441. doi: 10.1083/jcb.128.3.433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bergamaschi S., Binetti G., Govoni S., Wetsel W. C., Battaini F., Trabucchi M., Bianchetti A., Racchi M. Defective phorbol ester-stimulated secretion of beta-amyloid precursor protein from Alzheimer's disease fibroblasts. Neurosci Lett. 1995 Dec 1;201(1):1–5. doi: 10.1016/0304-3940(95)12168-4. [DOI] [PubMed] [Google Scholar]
  5. Bernini F., Didoni G., Bonfadini G., Bellosta S., Fumagalli R. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis. 1993 Dec;104(1-2):19–26. doi: 10.1016/0021-9150(93)90172-q. [DOI] [PubMed] [Google Scholar]
  6. Bodovitz S., Klein W. L. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem. 1996 Feb 23;271(8):4436–4440. doi: 10.1074/jbc.271.8.4436. [DOI] [PubMed] [Google Scholar]
  7. Bretscher M. S., Munro S. Cholesterol and the Golgi apparatus. Science. 1993 Sep 3;261(5126):1280–1281. doi: 10.1126/science.8362242. [DOI] [PubMed] [Google Scholar]
  8. Brown M. S., Ho Y. K., Goldstein J. L. The cholesteryl ester cycle in macrophage foam cells. Continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters. J Biol Chem. 1980 Oct 10;255(19):9344–9352. [PubMed] [Google Scholar]
  9. Criado M., Eibl H., Barrantes F. J. Effects of lipids on acetylcholine receptor. Essential need of cholesterol for maintenance of agonist-induced state transitions in lipid vesicles. Biochemistry. 1982 Jul 20;21(15):3622–3629. doi: 10.1021/bi00258a015. [DOI] [PubMed] [Google Scholar]
  10. Denizot F., Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986 May 22;89(2):271–277. doi: 10.1016/0022-1759(86)90368-6. [DOI] [PubMed] [Google Scholar]
  11. Ehlers M. R., Riordan J. F. Membrane proteins with soluble counterparts: role of proteolysis in the release of transmembrane proteins. Biochemistry. 1991 Oct 22;30(42):10065–10074. doi: 10.1021/bi00106a001. [DOI] [PubMed] [Google Scholar]
  12. Esch F. S., Keim P. S., Beattie E. C., Blacher R. W., Culwell A. R., Oltersdorf T., McClure D., Ward P. J. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science. 1990 Jun 1;248(4959):1122–1124. doi: 10.1126/science.2111583. [DOI] [PubMed] [Google Scholar]
  13. Glenner G. G., Wong C. W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984 May 16;120(3):885–890. doi: 10.1016/s0006-291x(84)80190-4. [DOI] [PubMed] [Google Scholar]
  14. Haass C., Koo E. H., Mellon A., Hung A. Y., Selkoe D. J. Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature. 1992 Jun 11;357(6378):500–503. doi: 10.1038/357500a0. [DOI] [PubMed] [Google Scholar]
  15. Haass C., Schlossmacher M. G., Hung A. Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B. L., Lieberburg I., Koo E. H., Schenk D., Teplow D. B. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 1992 Sep 24;359(6393):322–325. doi: 10.1038/359322a0. [DOI] [PubMed] [Google Scholar]
  16. Henriksson T., Barbour R. M., Braa S., Ward P., Fritz L. C., Johnson-Wood K., Chung H. D., Burke W., Reinikainen K. J., Riekkinen P. Analysis and quantitation of the beta-amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal antibody-based immunoassay. J Neurochem. 1991 Mar;56(3):1037–1042. doi: 10.1111/j.1471-4159.1991.tb02026.x. [DOI] [PubMed] [Google Scholar]
  17. Huang Y., von Eckardstein A., Wu S., Assmann G. Effects of the apolipoprotein E polymorphism on uptake and transfer of cell-derived cholesterol in plasma. J Clin Invest. 1995 Dec;96(6):2693–2701. doi: 10.1172/JCI118336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kahn J., Ingraham R. H., Shirley F., Migaki G. I., Kishimoto T. K. Membrane proximal cleavage of L-selectin: identification of the cleavage site and a 6-kD transmembrane peptide fragment of L-selectin. J Cell Biol. 1994 Apr;125(2):461–470. doi: 10.1083/jcb.125.2.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kang J., Lemaire H. G., Unterbeck A., Salbaum J. M., Masters C. L., Grzeschik K. H., Multhaup G., Beyreuther K., Müller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987 Feb 19;325(6106):733–736. doi: 10.1038/325733a0. [DOI] [PubMed] [Google Scholar]
  20. Kitaguchi N., Takahashi Y., Tokushima Y., Shiojiri S., Ito H. Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity. Nature. 1988 Feb 11;331(6156):530–532. doi: 10.1038/331530a0. [DOI] [PubMed] [Google Scholar]
  21. Klein I., Moore L., Pastan I. Effect of liposomes containing cholesterol on adenylate cyclase activity of cultured mammalian fibroblasts. Biochim Biophys Acta. 1978 Jan 4;506(1):42–53. doi: 10.1016/0005-2736(78)90433-9. [DOI] [PubMed] [Google Scholar]
  22. Klein U., Gimpl G., Fahrenholz F. Alteration of the myometrial plasma membrane cholesterol content with beta-cyclodextrin modulates the binding affinity of the oxytocin receptor. Biochemistry. 1995 Oct 24;34(42):13784–13793. doi: 10.1021/bi00042a009. [DOI] [PubMed] [Google Scholar]
  23. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  24. Lange Y. Cholesterol movement from plasma membrane to rough endoplasmic reticulum. Inhibition by progesterone. J Biol Chem. 1994 Feb 4;269(5):3411–3414. [PubMed] [Google Scholar]
  25. Liscum L., Underwood K. W. Intracellular cholesterol transport and compartmentation. J Biol Chem. 1995 Jun 30;270(26):15443–15446. doi: 10.1074/jbc.270.26.15443. [DOI] [PubMed] [Google Scholar]
  26. Löffler J., Huber G. Modulation of beta-amyloid precursor protein secretion in differentiated and nondifferentiated cells. Biochem Biophys Res Commun. 1993 Aug 31;195(1):97–103. doi: 10.1006/bbrc.1993.2015. [DOI] [PubMed] [Google Scholar]
  27. Mahley R. W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988 Apr 29;240(4852):622–630. doi: 10.1126/science.3283935. [DOI] [PubMed] [Google Scholar]
  28. Mahley R. W., Nathan B. P., Bellosta S., Pitas R. E. Apolipoprotein E: impact of cytoskeletal stability in neurons and the relationship to Alzheimer's disease. Curr Opin Lipidol. 1995 Apr;6(2):86–91. doi: 10.1097/00041433-199504000-00005. [DOI] [PubMed] [Google Scholar]
  29. Maruyama K., Kametani F., Usami M., Yamao-Harigaya W., Tanaka K. "Secretase," Alzheimer amyloid protein precursor secreting enzyme is not sequence-specific. Biochem Biophys Res Commun. 1991 Sep 30;179(3):1670–1676. doi: 10.1016/0006-291x(91)91767-7. [DOI] [PubMed] [Google Scholar]
  30. Mims M. P., Soma M. R., Morrisett J. D. Effect of particle size and temperature on the conformation and physiological behavior of apolipoprotein E bound to model lipoprotein particles. Biochemistry. 1990 Jul 17;29(28):6639–6647. doi: 10.1021/bi00480a013. [DOI] [PubMed] [Google Scholar]
  31. Mitchell D. C., Straume M., Miller J. L., Litman B. J. Modulation of metarhodopsin formation by cholesterol-induced ordering of bilayer lipids. Biochemistry. 1990 Oct 2;29(39):9143–9149. doi: 10.1021/bi00491a007. [DOI] [PubMed] [Google Scholar]
  32. Pandiella A., Massagué J. Multiple signals activate cleavage of the membrane transforming growth factor-alpha precursor. J Biol Chem. 1991 Mar 25;266(9):5769–5773. [PubMed] [Google Scholar]
  33. Ponte P., Gonzalez-DeWhitt P., Schilling J., Miller J., Hsu D., Greenberg B., Davis K., Wallace W., Lieberburg I., Fuller F. A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature. 1988 Feb 11;331(6156):525–527. doi: 10.1038/331525a0. [DOI] [PubMed] [Google Scholar]
  34. Ramchandran R., Sen G. C., Misono K., Sen I. Regulated cleavage-secretion of the membrane-bound angiotensin-converting enzyme. J Biol Chem. 1994 Jan 21;269(3):2125–2130. [PubMed] [Google Scholar]
  35. Sambamurti K., Shioi J., Anderson J. P., Pappolla M. A., Robakis N. K. Evidence for intracellular cleavage of the Alzheimer's amyloid precursor in PC12 cells. J Neurosci Res. 1992 Oct;33(2):319–329. doi: 10.1002/jnr.490330216. [DOI] [PubMed] [Google Scholar]
  36. Schroeder F., Jefferson J. R., Kier A. B., Knittel J., Scallen T. J., Wood W. G., Hapala I. Membrane cholesterol dynamics: cholesterol domains and kinetic pools. Proc Soc Exp Biol Med. 1991 Mar;196(3):235–252. doi: 10.3181/00379727-196-43185. [DOI] [PubMed] [Google Scholar]
  37. Selkoe D. J. Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci. 1994;17:489–517. doi: 10.1146/annurev.ne.17.030194.002421. [DOI] [PubMed] [Google Scholar]
  38. Sinha A. K., Shattil S. J., Colman R. W. Cyclic AMP metabolism in cholesterol-rich platelets. J Biol Chem. 1977 May 25;252(10):3310–3314. [PubMed] [Google Scholar]
  39. Sisodia S. S. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):6075–6079. doi: 10.1073/pnas.89.13.6075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Sisodia S. S., Koo E. H., Beyreuther K., Unterbeck A., Price D. L. Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. Science. 1990 Apr 27;248(4954):492–495. doi: 10.1126/science.1691865. [DOI] [PubMed] [Google Scholar]
  41. Sparks D. L., Scheff S. W., Hunsaker J. C., 3rd, Liu H., Landers T., Gross D. R. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994 Mar;126(1):88–94. doi: 10.1006/exnr.1994.1044. [DOI] [PubMed] [Google Scholar]
  42. Strittmatter W. J., Roses A. D. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A. 1995 May 23;92(11):4725–4727. doi: 10.1073/pnas.92.11.4725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., Roses A. D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1977–1981. doi: 10.1073/pnas.90.5.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Tanzi R. E., McClatchey A. I., Lamperti E. D., Villa-Komaroff L., Gusella J. F., Neve R. L. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. Nature. 1988 Feb 11;331(6156):528–530. doi: 10.1038/331528a0. [DOI] [PubMed] [Google Scholar]
  45. Wang X., Sato R., Brown M. S., Hua X., Goldstein J. L. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell. 1994 Apr 8;77(1):53–62. doi: 10.1016/0092-8674(94)90234-8. [DOI] [PubMed] [Google Scholar]
  46. Warner G. J., Stoudt G., Bamberger M., Johnson W. J., Rothblat G. H. Cell toxicity induced by inhibition of acyl coenzyme A:cholesterol acyltransferase and accumulation of unesterified cholesterol. J Biol Chem. 1995 Mar 17;270(11):5772–5778. doi: 10.1074/jbc.270.11.5772. [DOI] [PubMed] [Google Scholar]
  47. Weisgraber K. H., Innerarity T. L., Mahley R. W. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem. 1982 Mar 10;257(5):2518–2521. [PubMed] [Google Scholar]
  48. Weisgraber K. H., Roses A. D., Strittmatter W. J. The role of apolipoprotein E in the nervous system. Curr Opin Lipidol. 1994 Apr;5(2):110–116. doi: 10.1097/00041433-199404000-00007. [DOI] [PubMed] [Google Scholar]
  49. Wong L., Curtiss L. K., Huang J., Mann C. J., Maldonado B., Roheim P. S. Altered epitope expression of human interstitial fluid apolipoprotein A-I reduces its ability to activate lecithin cholesterol acyl transferase. J Clin Invest. 1992 Dec;90(6):2370–2375. doi: 10.1172/JCI116127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Yeagle P. L. Modulation of membrane function by cholesterol. Biochimie. 1991 Oct;73(10):1303–1310. doi: 10.1016/0300-9084(91)90093-g. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES